We are writing with regard to the article by Speit et al. (1) relating to the cytokinesis-block micronucleus (CBMN) assay and its application to in vitro studies. We feel that although the question addressed is relevant, the design of the study and the conclusions made are not appropriate and, furthermore, they are likely to cause confusion to inexperienced researchers considering applying the CBMN assay in in vitro and in vivo studies. These concerns are explained as follows:
1. The title of the article 'Insensitivity of the in vitro cytokinesis-block micronucleus assay with human lymphocytes for the detection of DNA damage present at the start of the cell culture' is incorrect and misleading because there is overwhelming evidence that the CBMN assay is highly sensitive to ionising radiation, radiomimetic compounds (e.g. bleomycin) and cross-linking agents (e.g. mitomycin-C) when lymphocytes are exposed before or at the start of the culture. The title should be amended to specifically indicate the chemicals that they claim to be genotoxic in vitro with the CBMN assay only at high doses (i.e. methyl methane sulphonate, ethylnitrosourea and styrene oxide) to avoid the confusion that is generated as consequence. 2. The observations in the article of Speit et al. (1) are not original because the relative insensitivity of the in vitro CBMN assay to agents that predominantly induce adducts and other excision-repairable lesions was already reported by Fenech and Neville in 1992 (2) . This article addressed, what was known for some time, that genotoxic agents that predominantly induce adducts do not cause acentric chromosome fragments that lead to formation of micronuclei (MN) within one mitotic cycle after exposure in G0. This is because the presence of an unrepaired adduct may only lead to abasic site formation and/or a single-strand break during DNA synthesis and that these lesions can only convert to double-strand breaks (DSBs), acentric fragments and MN in a second or third mitotic division. The agents that predominantly induce DNA adducts only induce chromatid gaps and chromatid breaks, which are not efficiently expressed as MN. It was for this reason that the cytosine arabinoside (ARA-C) protocol was developed because this allowed excision-repairable lesions induced in G0 or G1 to be converted to single-strand breaks before DNA synthesis in the first mitotic cycle by inhibiting the gap-filling step of base excision repair (3) . As a consequence, the accumulated breaks then become DSBs following DNA synthesis phase and the unrepaired or misrepaired DSBs are subsequently expressed as acentric chromosome fragments or dicentric chromosomes at metaphase, and MN and nucleoplasmic bridges in cytokinesis-blocked binucleated cells in the first division cycle, respectively. The ARA-C CBMN assay increased detection of DNA damage induced by agents that predominantly induce excision-repairable DNA lesions such as ultraviolet light and methylnitrosourea 10-fold and >20-fold respectively (2). Therefore, the proper protocol to detect in vitro excision-repairable DNA lesions, and agents that predominantly induce them, with the CBMN assay is to use the ARA-C protocol as described by Fenech and Neville in 1992 (2) and by Fenech in 2007 (4). 3. It is simply not correct to use the results from an in vitro study using a short-term 2-h exposure in G0 T lymphocytes to imply that scoring MN in binucleated T lymphocytes in the CBMN assay is not sensitive to chemical exposure in vivo. In fact, virtually all studies where exposure was properly documented, for example studies involving exposure to cytotoxic drugs in cancer chemotherapy (5-7), pesticides (8), polycyclic hydrocarbon exposure (9-11) and even styrene occupational exposure (12, 13) showed that the CBMN assay detected significant increases in DNA damage. Indeed, the studies from the Speit laboratory confirmed that in cancer chemotherapy patients MN were increased 300% in binucleated cells relative to controls, but not in mononucleated non-cultured cells (14) . This means that a wide range of genotoxic chemicals can induce persistent damage in vivo and this damage can be subsequently and efficiently expressed as MN in vivo. 4. As a key point, although MN frequency in lymphocytes can be reliably used as a biological dosimeter of exposure to genotoxins that efficiently induce MN in vitro and in vivo (e.g. ionising radiation), the MN frequency index is particularly important as a biomarker of early DNA damage events that are predictive for cancer (15) . We will restrict our comments to MN resulting from chromosome aberrations because whole chromosome loss was not the subject of the article. It is clear that most of the DNA damage that occurred before and just before blood sampling is normally repaired, but some DNA damage is not repaired or may be misrepaired, due to the type of mutagen, the phase of the cell cycle in which the cell was exposed, individual DNA repair deficiencies (16) and the level of exposure (17) . If not repaired, these DNA lesions will induce transmissible chromosome defects. It is precisely these 'defective cells' and not those where DNA was repaired that are important for biomonitoring because they constitute a flag for cancer risk (17) . Moreover, to discriminate between accumulated chromosome aberrations already present in vivo and recently expressed DNA damage (during ex vivo culture period), we recommended already in 2001 (18) to score MN frequencies in both binucleated and mononucleated T lymphocytes obtained with the standard CBMN assay for biomonitoring. This is an easy internal measure for the addressed question. Biomonitoring of occupational exposure to styrene (12, 13) confirmed the validity of this approach. 5. An important weakness of almost all in vitro studies that attempt to predict in vivo effects is that exposures are far too short compared with in vivo exposures, which are most often chronic exposures and, in the case of the article by Speit et al. (1) , it does not consider the fact that cells in vivo are exposed at all stages of the cell cycle not only at the G0 phase. This means that a significant proportion of G0 lymphocytes in the peripheral blood are very likely to have experienced genotoxic exposure during S phase during their maturation in spleen, thymus, lymph nodes and bone marrow, which could lead to persistent DNA damage or presence of MN in the mature quiescent cells in the peripheral blood. Therefore, the protocol in the micronucleus assay OECD guideline 487, which requires treatment at a time coincident with a large proportion of cells in S phase is clearly the correct procedure. However, it is important to note that in vitro chronic exposures over periods experienced in vivo (i.e. over 7 days or more) may ultimately be more appropriate as shown in recent studies with alcohol (19) and micronutrient deficiency (20) as this takes into account the adaptive response of cells and the cumulative effects of exposure resulting ultimately in a steady state higher DNA damage level as MN and other related nuclear anomalies such as nucleoplasmic bridges and nuclear buds. 6. The comparison of the CBMN assay with the comet assay using whole-blood cultures in the article by Speit et al. (1) is flawed because although the CBMN assay is specific to lymphocytes (because phytohaemagglutinin stimulates mainly T lymphocytes) the Comet assay results would have been confounded by a mixture of effects in leucocyte subsets including neutrophils that constitute about 61% of the leucocyte population as compared with only 33% for lymphocytes and 6% for other cell types (e.g. monocytes, eosinophils and basophils) in healthy adult subjects (21, 22) . Furthermore, human neutrophils possess inherent myeloperoxidase activity and have poor DNA repair activity as assessed using the comet assay, which would may make them more prone to DNA damage and cytotoxicity caused by xenobiotics (23, 24) . Also human monocytes are severely impaired in base and DNA doublestrand break repair that renders them vulnerable to oxidative stress and excessive apoptosis (25) . The authors should have done the comet assays specifically in isolated lymphocytes to eliminate these important confounding effects and provide a proper comparison with the lymphocyte CBMN assay. 7. Furthermore, the comet assay data may have also been further confounded by apoptotic or necrotic cell death. The authors used the nuclear division index (NDI) to indicate lack of toxicity, but NDI is not a measure of apoptosis or necrosis, it is simply a measure of the rate of division of surviving cells and, furthermore, an increase in necrosis or apoptosis does not necessarily result in a reduced NDI in surviving cells. An increase in necrosis or apoptosis in neutrophils, monocytes or lymphocytes in the whole-blood cultures could explain the apparent positive results with the comet assay. In our opinion, the Comet data are not reliable as obtained by Speit et al. (1) . In fact, there are important concerns about false-positive effects of necrosis and apoptosis in the comet assay and the 'Apo-Necro-Comet assay' described by Morley et al. (26) should have been used to distinguish DNA strand breaks in viable cells from DNA strand breaks caused by necrosis or early apoptosis. Furthermore, studies with sodium arsenite have led to the conclusion that apparent DNA damaging effects with the comet assay cannot be adequately interpreted if separate analysis of early induction of apoptosis is not performed because even after just 30 min of exposure Annexin positive (early apoptotic or late necrosis) cells were increased (27) . The results as presented by Speit et al. (1) do not exclude the possibility of confounding by apoptosis or necrosis (in neutrophils or lymphocytes) in the comet assay.
For all of these reasons, it is our strong view that although the question addressed is relevant (but not new) the conclusions of the article by Speit et al. (1) regarding the sensitivity of the CBMN assay are not correct, the extrapolations to in vivo application of the assay are inappropriate and the experimental design and protocols used were not suitable to come to a definite and accurate conclusion. We are concerned that without these additional corrections/commentaries, the article of Speit et al. will lead inexperienced scientists to incorrect interpretation of CBMN assay data and inappropriate experimental designs for studying in vitro and in vivo DNA damage in peripheral blood lymphocytes.
